Trandolapril

Trandolapril

Clinical data
Pregnancy category	US: D (Evidence of risk)
Routes of administration	Oral
ATC code	C09AA10 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	Trandolapril 80% (independent of concentration) Trandolaprilat 65 to 94% (concentration-dependent)
Metabolism	Hepatic
Elimination half-life	6 hours (trandolapril) 10 hours (trandolaprilat)
Excretion	Fecal and renal
Identifiers
IUPAC name (2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-ethoxycarbonyl-3-phenyl- propyl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole- 2-carboxylic acid
CAS Number	87679-37-6
PubChem CID	5484727
DrugBank	APRD01269
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H34N2O5
Molar mass	430.537 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Trandolapril is an ACE inhibitor used to treat high blood pressure, it may also be used to treat other conditions. It is marketed by Abbott Laboratories with the brand name Mavik®.

Pharmacology

Trandolapril is a prodrug that is deesterified to trandolaprilat. It is believed to exert its antihypertenive effect through the renin-angiotensin-aldosterone system. Trandolapril has a half life of about 6 hours, and trandolaprilat has a half life of about 10. Trandolaprilat has about 8 times the activity of its parent drug. Approximately 1/3 of Trandolapril and its metabolites are excreted in the urine, and about 2/3 of Trandolapril and its metabolites are excreted in the feces. Serum protein binding of trandolapril is about 80%.

Mode of action

Trandolapril acts by competitive inhibition of Angiotensin Converting Enzyme (ACE), a key enzyme in the renin-angiotensin system (RAS pathway) which plays an important role in regulating blood pressure. See ACE inhibitors for more information.

Side effects

Side effects reported for Trandolapril include nausea, vomiting, or diarrhea; headache; dry cough; dizziness or lightheadedness when sitting up or standing; hypotension or fatigue.

Possible Drug Interactions

Patients also on diuretics may experience an excessive reduction of blood pressure after initiation of therapy with Trandolapril. Trandolapril can reduce potassium loss caused by thiazide diuretics, and increase serum potassium when used alone. Therefore hyperkalemia is a possible risk. Increased serum lithium levels can occur in patients who are also on lithium. For more information see angiotensin converting enzyme (ACE) inhibitors.

Contraindications and Precautions

See ACE inhibitors for more information.

Pregnancy and Lactation

Category D

Trandolapril is teratogenic and can cause birth defects and even death of the developing fetus. The highest risk to the fetus is during the second and third trimester. When pregnancy is detected, Trandolapril should be discontinued as soon as possible.

Trandolapril should not be administed to nursing mothers.

Main article: ACE inhibitor

External links

• Mavik (PDF from manufacturer's website)
• Tarka (PDF from manufacturer's website)
• Trandolapril (patient information)
• Trandolapril Information - rxlist.com (Rxlist.com, The Internet Drug Index)

References

• Trandolapril Information - rxlist.com (Rxlist.com, The Internet Drug Index)

Template:ACE inhibitors

Template:WikiDoc Sources